- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Implantable loop recorder screening for AF may reduce stroke in elderly patients with higher NT-proBNP levels
Denmark: A new study has found that N-terminal pro-B-type natriuretic peptide (NT-proBNP) may be a useful marker for screening individuals for atrial fibrillation (AF) and stroke prevention, according to a study published in Circulation: AHA Journal.
The NT-proBNP has been found to be a powerful predictor of atrial fibrillation (AF) and stroke. The purpose of this study was to investigate NT-proBNP as a potential marker for screening efficacy in terms of AF yield and stroke prevention.
The study, which was conducted on a group of 6,004 AF-naïve individuals aged 70-90 years with additional stroke risk factors and was randomized 1:3, to investigate the efficacy of continuous screening with implantable loop recorder (ILR) and anticoagulation initiation upon detection of AF episodes ≥6 minutes, compared to usual care.
The study concluded with the following clinical takeaways:
1. NT-proBNP above the median was associated with an increased risk of AF diagnosis in both the ILR and Control groups.
2. Participants with NT-proBNP above the median had a higher risk of clinical events, including stroke or systemic embolism, stroke/SE/cardiovascular death, and all-cause death.
3. ILR screening was associated with significant reductions in stroke/SE and stroke/SE/cardiovascular death among participants with NT-proBNP above the median compared to usual care.
4. Analyzing NT-proBNP as a continuous variable yielded similar findings.
These findings suggest that NT-proBNP may be a useful marker for identifying individuals who would benefit from ILR screening for AF and subsequent anticoagulation therapy to prevent stroke. However, the authors caution that further studies are needed before clinical implementation.
“The study underscores the importance of early detection and management of AF in individuals with stroke risk factors, particularly in the elderly population. AF is a common heart condition that affects millions of people worldwide and is a major risk factor for stroke. Anticoagulation therapy has been shown to significantly reduce the risk of stroke in individuals with AF, but early detection and management are crucial for optimal outcomes.” said the researchers of the study.
Reference:
Xing L., Diederichsen S., Højberg S., Krieger D., et al.; Effects of Systematic Atrial Fibrillation Screening According to N-Terminal Pro-B-Type Natriuretic Peptide: a Secondary Analysis of the Randomized LOOP Study; Circulation. 2023;0; doi: https://doi.org/10.1161/CIRCULATIONAHA.123.064361
Dr. Mahalakshmi Sivashankaran joined Medical Dialogues as an Intern in 2023. She is a BDS graduate from Manipal College of Dental Sciences, Mangalore Batch 2022, and worked as a Junior Resident at VMMC & Safdarjung Hospital at the Department of Dental Surgery till January 2023. She has completed a Diploma in Executive Healthcare management from the Loyola Institute of Business Administration, developing skills in Healthcare Management and Administration. She covers several medical specialties including Dental, ENT, Diagnostics, Pharmacology, Neurology, and Cardiology.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751